bluebird bio (NASDAQ:BLUE) Rating Increased to Neutral at JPMorgan Chase & Co.

bluebird bio (NASDAQ:BLUE) was upgraded by analysts at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a report released on Monday,Briefing.com Automated Import reports.

BLUE has been the subject of a number of other research reports. Bank of America cut shares of bluebird bio from a “buy” rating to a “neutral” rating and cut their price target for the stock from $60.00 to $10.00 in a research note on Friday, November 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $80.00 price objective on shares of bluebird bio in a report on Friday, November 15th. Barclays raised their price objective on shares of bluebird bio from $2.00 to $40.00 and gave the company an “overweight” rating in a research note on Tuesday, December 31st. Finally, StockNews.com assumed coverage on bluebird bio in a report on Friday, December 20th. They issued a “sell” rating for the company. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have given a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $49.14.

bluebird bio Stock Performance

Shares of bluebird bio stock opened at $4.08 on Monday. The firm has a market capitalization of $39.66 million, a P/E ratio of -0.11 and a beta of 0.68. The company has a current ratio of 0.51, a quick ratio of 0.33 and a debt-to-equity ratio of 0.37. bluebird bio has a 12 month low of $4.00 and a 12 month high of $38.40. The business’s fifty day simple moving average is $7.81 and its 200 day simple moving average is $9.47.

Hedge Funds Weigh In On bluebird bio

Large investors have recently made changes to their positions in the company. BNP Paribas Financial Markets increased its holdings in shares of bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after buying an additional 355,562 shares during the last quarter. FMR LLC increased its position in bluebird bio by 8.1% during the third quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after buying an additional 186,903 shares during the period. Barclays PLC grew its holdings in shares of bluebird bio by 273.7% during the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after buying an additional 184,605 shares during the last quarter. Geode Capital Management LLC grew its position in bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after buying an additional 166,771 shares during the last quarter. Finally, Verition Fund Management LLC purchased a new position in shares of bluebird bio during the 3rd quarter worth approximately $42,000. 87.43% of the stock is currently owned by institutional investors and hedge funds.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.